Metaxalone submicron

Drug Profile

Metaxalone submicron

Alternative Names: IC-1201; ICE-1201; Submicron metaxalone

Latest Information Update: 09 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator iCeutica
  • Developer Iroko Pharmaceuticals
  • Class Muscle relaxants; Oxazolidinones; Small molecules
  • Mechanism of Action Central nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Musculoskeletal disorders

Most Recent Events

  • 09 Feb 2017 Metaxalone submicron is still in phase I development for Musculoskeletal disorders in USA (iCeutica pipeline, February 2017)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Musculoskeletal-disorders in USA (PO, Tablet)
  • 12 Sep 2013 Top-line pharmacokinetics & adverse events data from a phase I trial in Healthy volunteers released by iCeutica
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top